Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Colice

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 27, 2007
Use of inhaled corticosteroids and healthcare costs in mild persistent asthmaGene Colice, Eric Q Wu, Howard Birnbaum, et al.
Journal of Asthma and Allergy|January 20, 2021
Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b StudyJonathan Corren, Martin Karpefors, Åsa Hellqvist, et al.
Immunotherapy|March 15, 2018
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development programReynold A Panettieri, Millie Wang, Martin Braddock, et al.
Drug Safety|February 8, 2018
Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic ReviewMartin Braddock, Nicola A Hanania, Amir Sharafkhaneh, et al.
Journal of Asthma and Allergy|April 28, 2021
Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled AsthmaSady Alpizar, Ayman Megally, Claudia Chen, et al.
Journal of Asthma and Allergy|February 11, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A <i>Post Hoc</i> Analysis of the Phase 2b PATHWAY StudyClaire Emson, Jonathan Corren, Kinga Sałapa, et al.
Chest|October 6, 2007
Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition)Douglas C McCrory, Sandra Zelman Lewis, Julia Heitzer, et al.
Respiratory Research|October 22, 2020
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthmaAndrew Menzies-Gow, Sandhia Ponnarambil, John Downie, et al.
Clinical Therapeutics|December 31, 2020
Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy VolunteersYanan Zheng, Lubna Abuqayyas, Ayman Megally, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 17, 2021
Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthmaTuyet-Hang Pham, Claudia Chen, Gene Colice, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 27, 2007
Use of inhaled corticosteroids and healthcare costs in mild persistent asthmaGene Colice, Eric Q Wu, Howard Birnbaum, et al.
Journal of Asthma and Allergy|January 20, 2021
Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b StudyJonathan Corren, Martin Karpefors, Åsa Hellqvist, et al.
Immunotherapy|March 15, 2018
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development programReynold A Panettieri, Millie Wang, Martin Braddock, et al.
Drug Safety|February 8, 2018
Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic ReviewMartin Braddock, Nicola A Hanania, Amir Sharafkhaneh, et al.
Journal of Asthma and Allergy|April 28, 2021
Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled AsthmaSady Alpizar, Ayman Megally, Claudia Chen, et al.
Journal of Asthma and Allergy|February 11, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A <i>Post Hoc</i> Analysis of the Phase 2b PATHWAY StudyClaire Emson, Jonathan Corren, Kinga Sałapa, et al.
Chest|October 6, 2007
Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition)Douglas C McCrory, Sandra Zelman Lewis, Julia Heitzer, et al.
Respiratory Research|October 22, 2020
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthmaAndrew Menzies-Gow, Sandhia Ponnarambil, John Downie, et al.
Clinical Therapeutics|December 31, 2020
Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy VolunteersYanan Zheng, Lubna Abuqayyas, Ayman Megally, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 17, 2021
Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthmaTuyet-Hang Pham, Claudia Chen, Gene Colice, et al.
Pageof 7